Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2025-10 · 69 (10)
DOI: 10.1128/aac.00368-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025-10. Verfasst von Mengyun Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Drug Discovery Institute, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Benzimidazoles, Antitubercular Agents, Bacterial Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
New anti-tuberculosis (TB) drugs with novel modes of action are in great demand due to the complex treatment regimens as well as the rising number of multidrug-resistant TB cases. We recently re-evaluated a few 2,5,6-trisubstituted benzimidazole derivatives (SBZ) previously demonstrated to have potent antitubercular activity. These compounds displayed favorable MICs and significantly reduced bacterial counts in an acute mouse infection model. Although this antitubercular lead series was initially reported to inhibit mycobacterial cell division, our findings suggest that its primary activity likely involves other cellular targets. By using bacterial cytological profiling, we observed that SBZ-treated Mycobacterium tuberculosis cells exhibit cell wall-damaging phenotypes resembling those caused by known cell wall biosynthesis inhibitors, such as AU1235 and SQ109, that mostly target the membrane protein large 3 (MmpL3). Whole-cell assays further supported the findings by showing activation of the iniBAC operon and accumulation of intracellular ATP. The antitubercular activity of SBZs was tested against engineered mycobacterial strains that have the transcriptionally regulated mmpL3 gene expression, confirming that SBZs engage the MmpL3 target in the cell. Strains with mutations in mmpL3 exhibited either low- or high-level resistance to the SBZs. A molecule docking model is proposed, based on a high-resolution crystal structure of MmpL3, which could be useful in reconciling the inhibition mechanism and suggesting a further development of MmpL3 inhibitor starting with the SBZ scaffold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Health Drug Discovery Institute, Beijing, China.
- Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
- Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York, USA.
- Linnaeus Bioscience Inc., San Diego, California, USA.
- Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
ORCID-Profile: Mengyun Zhang, Dirk Schnappinger, Tanya Parish, Shawn Chen
Förderung
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Zhang, M., Allen, R., Ames, L., Engelhart, C. A., Quach, D., Lv, X., Xiao, G., Wang, H., Wang, J., Zhou, L., Pan, M., Sugie, J., Pogliano, J., Schnappinger, D., Parish, T., & Chen, S. (2025). Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 69(10). https://doi.org/10.1128/aac.00368-25
Vancouver
Zhang M, Allen R, Ames L, Engelhart CA, Quach D, Lv X, et al. Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025;69(10). doi:10.1128/aac.00368-25
BibTeX
@article{Zhang2025,
author = {Zhang, Mengyun and Allen, Renee and Ames, Lauren and Engelhart, Curtis A and Quach, Diana and Lv, Xiaoying and Xiao, Genhui and Wang, Heng and Wang, Jinglan and Zhou, Liangliang and Pan, Miaomiao and Sugie, Joseph and Pogliano, Joe and Schnappinger, Dirk and Parish, Tanya and Chen, Shawn},
title = {Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {10},
doi = {10.1128/aac.00368-25}
}
EUVIMED